PET/MRI in prostate cancer: a systematic review and meta-analysis
- PDF / 532,301 Bytes
- 15 Pages / 595.276 x 790.866 pts Page_size
- 114 Downloads / 179 Views
REVIEW ARTICLE
PET/MRI in prostate cancer: a systematic review and meta-analysis Laura Evangelista 1 Pietro Zucchetta 1
&
Fabio Zattoni 2 & Gianluca Cassarino 1 & Paolo Artioli 1 & Diego Cecchin 1 & Fabrizio dal Moro 2,3 &
Received: 2 July 2020 / Accepted: 31 August 2020 # The Author(s) 2020
Abstract Aim In recent years, the clinical availability of scanners for integrated positron emission tomography (PET) and magnetic resonance imaging (MRI) has enabled the practical potential of multimodal, combined metabolic-receptor, anatomical, and functional imaging to be explored. The present systematic review and meta-analysis summarize the diagnostic information provided by PET/MRI in patients with prostate cancer (PCa). Materials and methods A literature search was conducted in three different databases. The terms used were “choline” or “prostate-specific membrane antigen - PSMA” AND “prostate cancer” or “prostate” AND “PET/MRI” or “PET MRI” or “PET-MRI” or “positron emission tomography/magnetic resonance imaging.” All relevant records identified were combined, and the full texts were retrieved. Reports were excluded if (1) they did not consider hybrid PET/MRI; or (2) the sample size was < 10 patients; or (3) the raw data were not enough to enable the completion of a 2 × 2 contingency table. Results Fifty articles were eligible for systematic review, and 23 for meta-analysis. The pooled data concerned 2104 patients. Initial disease staging was the main indication for PET/MRI in 24 studies. Radiolabeled PSMA was the tracer most frequently used. In primary tumors, the pooled sensitivity for the patient-based analysis was 94.9%. At restaging, the pooled detection rate was 80.9% and was higher for radiolabeled PSMA than for choline (81.8% and 77.3%, respectively). Conclusions PET/MRI proved highly sensitive in detecting primary PCa, with a high detection rate for recurrent disease, particularly when radiolabeled PSMA was used. Keywords Prostate cancer . Positron emission tomography . Magnetic resonance imaging . PSMA . Choline
Introduction The availability of tracers other than 18f-fluorodeoxyglucose (FDG) suggests new opportunities for the diagnosis and This article is part of the Topical Collection on Oncology - Genitourinary Electronic supplementary material The online version of this article (https://doi.org/10.1007/s00259-020-05025-0) contains supplementary material, which is available to authorized users. * Laura Evangelista [email protected] 1
Nuclear Medicine Unit, Department of Medicine, Padova University Hospital, Via Giustiniani 2, Padova, Italy
2
Urology Unit, Department of Medicine, Udine University Hospital, Udine, Italy
3
Urology Unit, Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy
management of prostate cancer (PCa). The use of different radiopharmaceuticals, such as radiolabeled choline, or radiolabeled ligands of prostate-specific membrane antigen (PSMA), has a significant impact in various clinical settings, from initial staging to the detecti
Data Loading...
